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Abstract
Background: Despite advances in surgery, radiotherapy, and chemotherapy, pancreatic adenocarcinoma often
progresses rapidly and causes death. The physical decline of these patients is expected to impact their quality of
life (QoL). Therefore, in addition to objective measures of effectiveness, the evaluation of health-related QoL should
be considered a matter of major concern when assessing therapy outcomes.
Methods: Observational, prospective, multicenter study including patients with metastatic pancreatic adenocarcinoma
who started first-line chemotherapy in 12 Spanish centers. Treatment and clinical characteristics were recorded at
baseline. Patients’ health-related quality of life, ECOG, and Karnofsky index were measured at baseline, at Days 15 and
30, and every four weeks up to 6months of chemotherapy. Health-related quality of life was measured using the
EORTC-QLQ-C30 and EQ-5D questionnaires. Other endpoints included overall survival and progression-free survival.
Results: The study sample included 116 patients (median age of 65 years). Mean (SD) scores for the QLQ-C30 global
health status scale showed a significant increasing trend throughout the treatment (p = 0.005). Patients with either a
Karnofsky index of 70–80 or ECOG 2 showed greater improvement in the QLQ-C30 global health status score than the
corresponding groups with better performance status (p≤ 0.010). Pain, appetite, sleep disturbance, nausea, and
constipation significantly improved throughout the treatment (p < 0.005). Patients with QLQ-C30 global health status
scores ≥50 at baseline had significantly greater overall survival and progression-free survival (p = 0.005 and p = 0.021,
respectively). No significant associations were observed regarding the EQ-5D score.
Conclusions: Most metastatic pancreatic adenocarcinoma patients receiving first-line chemotherapy showed an
increase in health-related quality of life scores throughout the treatment. Patients with lower performance status and
health-related quality of life at baseline tended to greater improvement. The EORTC QLQ-C30 scale allowed us to
measure the health-related quality of life of metastatic pancreatic adenocarcinoma patients receiving first-line
chemotherapy.
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Background
Despite recent advances in chemotherapy treatments,
metastatic pancreatic adenocarcinoma (mPAC) remains
incurable and survival rates are still low [1]. In the ab-
sence of treatments achieving long-term survival,
chemotherapy aims to slow tumor progression and re-
lieve symptoms [2, 3]. However, mPAC is an aggressive
disease, and the burden of physical symptoms, together
with the adverse effects of chemotherapy, lead to pa-
tients’ rapid physical decline and the subsequent deteri-
oration of their quality of life (QoL) [2, 3]. In this
scenario, health-related quality of life (HRQoL) becomes
a significant concern in the management of patients with
mPAC [4, 5].
Given the acknowledged importance of HRQoL, sev-
eral clinical trials have reported HRQoL and other QoL-
related outcomes in mPAC patients [5, 6]. Typically,
trials including mPAC report a remarkable burden of
toxicities associated with chemotherapy regimens.
Nevertheless, some of these trials provide supportive evi-
dence that favor chemotherapy in terms of HRQoL, par-
ticularly in patients who responded to it [3, 6]. In line
with these observations, global HRQoL and HRQoL-
related outcomes, such as pain and fatigue, were associ-
ated with survival in the clinical trial setting [7–10].
However, the methodologies used to evaluate HRQoL—
usually introduced as secondary endpoints—were het-
erogeneous, thus they precluded comparisons between
studies, often leading to inconsistent results [5, 6]. Fur-
thermore, thorough selection criteria from randomized
controlled trials (e.g., patients with relatively good phys-
ical status) are unlikely to reflect a real-life practice sce-
nario. To date, real-world data is limited to a few studies
proving the association between HRQoL and survival
[11–15], and the positive impact of nab-paclitaxel plus
gemcitabine treatment in HRQoL of patients with partial
response or stable disease [16].
The American Society of Clinical Oncology (ASCO)
defines clinically meaningful outcomes in the clinical
trial setting as a balance between toxicity and efficacy,
stressing the importance of HRQoL measures as indica-
tors of toxicity [17]. Similarly, real-life studies recom-
mend routine assessments of HRQoL to guide treatment
decisions [18]. In this observational prospective study,
we describe the evolution of HRQoL in patients with
mPAC treated with first-line chemotherapy in routine
clinical practice, and analyze patients’ clinical character-
istics that may influence their HRQoL.
Methods
Study design and population
This was an observational, prospective, multicenter
study including patients with histologically confirmed
mPAC (either recurrent or de novo) from 12 Spanish
centers, who had started first-line chemotherapy. Adult
patients (i.e., aged ≥18 years) with a Karnofsky Index
(KI) ≥70 and a life expectancy ≥6 months, who attended
routine follow-up visits between October 2014 and Oc-
tober 2015, were consecutively included in the study. No
other recruitment sources were considered. Patients that
were pregnant or breastfeeding, participating in a clinical
trial, or unable to understand or answer questions re-
lated to their health were excluded from the study. Base-
line demographic and clinical data were collected from
the medical records at the initiation visit (i.e., at study
entry, before starting the first-line treatment). Assess-
ments, which were scheduled to match routine visits,
were performed at baseline, at Days 15 and 30, and every
4 weeks up to 6 months after starting chemotherapy
(Treatment Period). After this time, patients were
followed up every 6 months for up to 18months to as-
sess survival (Follow-Up Period).
Endpoints, variables and assessments
The primary endpoint was the evolution of HRQoL in
patients with mPAC treated with first-line chemotherapy
in a routine clinical practice setting. HRQoL was
assessed using two self-administered questionnaires: the
European Organization for Research and Treatment of
Cancer (EORTC) Quality of Life Questionnaire (QLQ-
C30) (Version 3.0), and the European Quality of Life-5
Dimensions (EQ-5D). The QLQ-C30 is a 30-item,
cancer-specific multidimensional questionnaire designed
for prospective clinical studies that includes five func-
tional scales (role, physical, emotional, cognitive and so-
cial functioning), three symptom scales (fatigue, pain,
and nausea and vomiting), a global health and quality-
of-life scale, additional specific symptoms commonly re-
ported by cancer patients (dyspnea, loss of appetite,
sleep disturbance, constipation, and diarrhea), and the
perceived financial impact of the disease and treatment
[19]. The EQ-5D is a 5-item generic measure of health
status, including five dimensions (mobility, self-care,
usual activities, pain/discomfort and anxiety/depression)
and a Visual Analog Scale (VAS) [20]. Both question-
naires, which have been translated to Spanish and vali-
dated in the Spanish population [21, 22], were
administered during routine follow-up visits at baseline
and at each visit during the Treatment Period.
Baseline demographic characteristics considered in the
study included age, sex, and weight loss in the last 3
months. Clinical and treatment characteristics included
relevant concomitant diseases, date of diagnosis of the pri-
mary tumor, location of the metastatic disease, previous
adjuvant treatments for non-metastatic disease (if any)—
regimen, number of cycles, start and completion dates,
and response—, and first-line treatment prescribed
(schedule and initiation date). Together with the
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administration of HRQoL questionnaires, routine assess-
ments were performed at baseline and during the 6-
month Treatment Period, including blood tests, biochem-
istry, tumor evaluation, performance status (PS) (ECOG
and KI), treatment modification, and concomitant medica-
tion. Other variables were reasons for discontinuation of
chemotherapy, recorded during the Treatment and
Follow-Up Periods, dose modifications and adverse events,
recorded during the Treatment Period. Adverse events
(AE) were classified according to the Common Termin-
ology Criteria for Adverse Events (CTC-AE, version 4.02)
of the National Cancer Institute (NCI) (http://ctep.cancer.
gov/reporting/ctc.html).
Statistical analysis
Categorical variables and outcomes were presented as
frequencies and percentages, whereas continuous vari-
ables and outcomes were presented as mean and stand-
ard deviation (SD), or as median and interquartile range
(Q1,Q3). Categorical outcomes were compared using the
Chi-Square test or the Fisher’s exact test. Correspond-
ingly, continuous outcomes were compared using the T-
Test, the ANOVA, or their non-parametric counterparts
Wilcoxon or Kruskal-Wallis tests. OS and PFS curves
were plotted using the Kaplan-Meier estimator, and
compared using the log-rank test. Survival analyses are
described by median and 95% confidence interval (CI).
The improvement or deterioration in HRQoL was de-
fined as an increase or decrease of ≥5 points in the
EORTC QLQ-C30 global health status score with re-
spect to baseline [23]. Overall changes in the score
throughout the study visits were assessed using the ad-
justed linear mixed model. The significance level for all
analyses was set at a two-sided α = 0.05.
To estimate the minimum sample size needed, we as-
sumed a rate of QoL improvement of 5%. The rate of
QoL improvement was defined as a minimum increase
of 5–10 points in EORTC QLQ-C30 global health status
scores with respect to baseline. Based on this assump-
tion, a sample size of 110 patients was deemed necessary
to estimate the proportion of patients with an improve-
ment in QoL 6 months after starting first-line chemo-
therapy with a ± 4.1% precision and a 95% CI. Presuming
that 10% of patients may not complete the EORTC
QLQ-C30, the approximate number of patients included
in the study was 120. All analyses were performed using
the statistical SAS software for Windows (version 9.4).
Results
Patient characteristics and treatment outcome
Of the 120 patients recruited, four were excluded for not
having a first-line chemotherapy regimen scheduled (n =
1), being enrolled in a clinical trial (n = 1), declining to
participate in the study for personal reasons after signing
the informed consent (n = 1), and withdrawing for not
having started treatment (n = 1). The resulting study
sample included 116 patients, of which 101 (87.1%) had
concomitant diseases, with a median (Q1, Q3) age of
65.0 (59.5, 71.5) years and a median (Q1, Q3) Body Mass
Index (BMI) of 23.9 (22.2, 26.6) kg/m2. Table 1 summa-
rizes the demographic and clinical characteristics of
study patients at baseline and main treatment
characteristics.
Of these 116 patients, 113 (97.4%) started chemother-
apy in the study setting and were treated for a median
(Q1, Q3) of 3.9 (1.4, 6.7) months. Median OS was 9.0
months (95% CI 6.5–11.1) and median PFS was 6.0
months (95% CI 4.6–7.8). ORR was 32.6%, with three
(3.4%) and 24 (27.6%) patients achieving complete and
partial responses, respectively; 32 patients (36.8%) had
stable disease. The number of patients assessed gradually
declined during the Treatment Period due to death or
disease progression (and subsequent start of second-line
regimens), with 40 (34.2%) study patients remaining at
the end of the 6-month treatment, and 22 (19.0%) com-
pleting all study visits.
Overall, 112 patients (96.6%) had 962 adverse events
(AEs), of which 111 were serious, 390 were related to
treatment, and 171 were of grade 3–5. The most fre-
quent grade 3–5 AEs were neutropenia (32 events), as-
thenia (14 events), thrombocytopenia (7 events),
pneumonia (6 events), pyrexia (6 events), febrile neutro-
penia (6 events), diarrhea (5 events), and anemia (5
events). Table 2 summarizes the frequency of most com-
mon treatment-related grade ≥ 3 AEs, classified by Sys-
tem Organ Class.
Evolution of HRQoL
The adjusted linear mixed model revealed a significant
difference in QLQ-C30 global health status scores
throughout the Treatment Period (p = 0.005), with
scores showing an increasing trend at each visit. Overall,
mean (SD) scores increased from 53.7 (24.6) at baseline
to 66.7 (18.1) at the 6-month visit. Furthermore, at each
of the follow-up visits, the percentage of patients with
better QLQ-C30 global health status scores than at base-
line was ≥46.8% (Fig. 1). Fifty-seven (65.5%) patients im-
proved their HRQoL in at least one visit, 15 (17.2%)
showed a decline or a stable score, and 15 (17.2%)
showed a decline in all visits. Of the 15 patients showing
only deterioration in HRQoL compared to baseline, 13
(86.7%) had QLQ-C30 global health status scores ≥50 at
baseline. Overall, HRQoL deterioration was more fre-
quent in patients with higher QLQ-C30 global health
status scores at baseline: the percentage of patients with
deterioration at each study visit ranged from 24 to 50%
and from 6 to 15% in patients with baseline QLQ-C30
global health status scores ≥50 and < 50, respectively
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(p < 0.0001). EQ-5D (dimensions and VAS) did not
change significantly throughout the Treatment Period.
Regarding the symptom scales included in the QLQ-
C30, the ones assessing pain, appetite, and sleep disturb-
ance improved throughout the treatment, as shown by a
significant decrease in their mean scores (Fig. 2). Mean
scores for nausea and constipation also decreased, albeit
modestly, whereas mean scores for fatigue, dyspnea,
diarrhea and financial impact did not show statistically
significant differences throughout the Treatment Period
(p = 0.63, p = 0.64, p = 0.06, and p = 0.22, respectively).
Of all variables analyzed for their influence on
HRQoL, baseline PS and treatment response significantly
influenced QLQ-C30 global health status scores. Patients
with either KI of 70–80 or ECOG 2 at baseline showed a
significantly greater improvement in HRQoL than the
corresponding groups with better PS, reaching similar
QLQ-C30 global health status scores after 2 months of
chemotherapy (Fig. 3). Regarding treatment response,
baseline QLQ-C30 global health status scores were simi-
lar in patients whose best response during first-line
treatment was either partial/complete or stable disease
and in patients with progression as best response. How-
ever, patients whose best response was partial/complete
or stable disease had significantly higher QLQ-C30 glo-
bal health status scores at each study visit during the
first 3 months than those with progression as best re-
sponse (Fig. 4). No significant associations were ob-
served with EQ-5D scores.
Relationship between health status measures and survival
Of all baseline parameters analyzed for their potential
role as prognosis factors for survival, KI and QLQ-C30
global health status scores showed a significant associ-
ation with OS and/or PFS (Fig. 5). Patients with baseline
KI of 90–100 had a significantly higher OS (but not a
higher PFS) than patients with baseline KI of 70–80. Pa-
tients with baseline QLQ-C30 global health status scores
≥50 had a significantly higher OS and PFS than those
scoring < 50. Weight loss in the previous 3 months (>
10% vs. < 10%) did not have a significant influence on
OS and PFS.
Discussion
In this observational prospective study, we found that
patients receiving any first-line chemotherapy treatment
in routine clinical practice experienced positive changes
in various health domains, resulting in an improvement
of the HRQoL; this improvement was more notorious in
patients with poorer HRQoL at treatment start ―there-
fore, with most room for improvement. Mean scores of
the QLQ-C30 global scale and pain, appetite, sleep dis-
turbance, nausea, and constipation symptom scales im-
proved throughout the chemotherapy treatment,
Table 1 Characteristics of study patients and treatment
Demographic characteristics




Diagnosis, n (%) (n = 116)
Metastatic after relapse/progression 25 (21.6)
De novo metastatic 91 (78.4)
% Weight loss in the last 3 mo (median, Q1, Q3) (n = 74) 9.2 (4.5, 14.1)
Weight loss > 10%, n (%) 33 (44.6)
CA 19.9 UI/mL (median, Q1, Q3) (n = 90) 725.7 (83.0, 7323.0)




ECOG Performance Status, n (%) (n = 103)
0–1 84 (81.6)
2 19 (18.4)
Karnofsky Index, n (%) (n = 115)
90–100 60 (52.2)
70–80 55 (47.8)
Treatment characteristics and outcome
Treatment, n (%) (n = 113)
Gemcitabine + nab-paclitaxel 73 (64.6)
Gemcitabine monotherapy 21 (18.6)
FOLFIRINOX or mFOLFIRINOX 14 (12.4)
Other combinations 5 (4.4)
Treatment schedule, n (%) (n = 101)
Patients with any change in the dose or schedule 57 (56.4)
Patients with any delay in the treatment 59 (58.4)
Reasons for treatment discontinuation, n (%) (n = 111)a
Progression 60 (54.1)
Toxicity 15 (13.5)
Clinical deterioration 15 (13.5)
Lost to follow-up 1 (0.9)
Voluntary withdrawal of the study 1 (0.9)
Death 3 (2.7)
Other reasons 19 (17.1)
Best response obtained in the first-line treatment, n (%) (n = 87)
Complete response 3 (3.4)
Partial response 24 (27.6)
Stable disease 32 (36.8)
Progression 28 (32.2)
aPatients could have more than one reason for treatment discontinuation
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whereas scores from the EQ-5D questionnaire (dimen-
sions and VAS) remained unchanged. The evolution of
HRQoL throughout the first-line treatment, measured
using the QLQ-C30 global health status score, was sig-
nificantly influenced by patients’ PS and treatment re-
sponse. Baseline QLQ-C30 global health status scores
influenced OS and PFS, suggesting a prognostic value
for this factor.
In this study, two instruments were used to measure
HRQoL: the EORTC QLQ-C30 scale and the EQ-5D.
While QLQ-C30 showed good responsiveness and was
sensitive to changes in HRQoL throughout the Treat-
ment Period, EQ-5D (questionnaire and VAS) did not
reflect any changes in HRQoL. This finding is in line
with a previous observational study in patients with
mPAC, in which QLQ-C30, but not EQ-5D, enabled to
identify changes in HRQoL [16]. In contrast, another
clinical trial reported significant changes in the scores of
pain symptoms using EQ-5D in patients with advanced
pancreatic cancer [24]. To our knowledge, very few stud-
ies on mPAC patients used EQ-5D to assess HRQoL,
likely because other cancer-specific tools, such as QLQ-
C30 and cancer site-specific instruments, are available.
In fact, the National Cancer Institute of Canada Clinical
Trial Group chose QLQ-C30 as a standard questionnaire
in clinical trials [25]. Even though EQ-5D lacked sensi-
tivity, its response rates were slightly higher than those
of the QLQ-C30 questionnaire: mean response rate
throughout study visits was 79.0 and 76.1% for EQ-5D
dimensions and VAS, respectively, and 70.3% for the
complete QLQ-C30 questionnaire. The EORTC QLQ-
C30 global health status score, used to investigate corre-
lations with baseline PS, treatment response and progno-
sis, reached a mean response rate of 78.6% throughout
the study. While a consensus on acceptable response
rates for patient-reported outcomes remains unestab-
lished, a 70–80% response rate can be considered rea-
sonable to good [26]. Although assessing the validity of
these questionnaires was out of the scope of our study,
the sensitivity observed with the QLQ-C30 questionnaire
Table 2 Common treatment-related adverse events (> 1% of
patients) of grade ≥ 3 classified by System Organ Class and
Preferred Term, (n = 113)
No. (%)












Fig. 1 Qualitative changes in QLQ-C30 global health status scale scores at each of the study visits throughout the treatment period. The number
of patients experiencing improvement, stability or deterioration in their HRQoL is presented as a percentage over the total of patients attending
each of the visits
Laquente et al. BMC Palliative Care          (2020) 19:103 Page 5 of 11
suggests it is suitable for measuring changes in HRQoL
of mPAC patients undergoing first-line chemotherapy.
Despite the importance of assessing HRQoL to evalu-
ate the balance between toxicity and effectivity of
chemotherapy, studies focusing on changes in HRQoL
of mPAC patients treated with chemotherapy are scarce,
heterogeneous, and have often reported conflicting re-
sults. Kristensen et al. systematically reviewed 23 clinical
trials in advanced pancreatic cancer, which included the
assessment of HRQoL as a secondary endpoint. Of the
14 studies reporting changes in HRQoL compared to
baseline, five observed an improvement in at least one
treatment arm, three observed worsening in at least one
treatment arm, and the remaining seven reported no
change [6]. Our results, showing a statistically significant
13-point increase in mean QLQ-C30 global health status
scores from baseline to Month 6, are in line with the five
studies reporting an improvement in HRQoL in the trial
setting [7, 9, 27–29]. Likewise, the decrease in pain
scores during the Treatment Period in our cohort, which
Fig. 2 Evolution of the mean EORTC QLQ-C30 scores for fatigue, nausea, pain, dyspnea and sleep disturbance (A); and appetite loss, constipation,
diarrhea and financial impact (B) throughout the treatment period
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indicates an improvement of this symptom, are in line
with the seven studies (out of eight clinical trials report-
ing on the evolution of pain scores) showing an im-
provement in pain [9, 28, 30–34]. Even though the mean
QLQ-C30 global health status score improved in our
study population throughout the Treatment Period, 17%
of patients showed only deterioration. Interestingly, pa-
tients with worse HRQoL at baseline were more likely to
show an improvement throughout the Treatment Period
than those with better HRQoL at baseline.
Asides from assessing the evolution of HRQoL in real-
life patients receiving first-line chemotherapy, we inves-
tigated the prognostic value of baseline HRQoL in our
study population. Previous clinical trials and real-life
studies have demonstrated that baseline HRQoL and
subsequent changes during treatment (global and
Fig. 3 Evolution of the mean QLQ-C30 global health status scale scores according to the baseline Karnosfky Index (A) and ECOG (B) throughout
the treatment period
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subscales) are associated with survival of patients with
pancreatic cancer [8, 9, 11–14, 35]. Our results con-
firmed this trend in a real-life setting, with patients scor-
ing ≥50 in the QLQ-C30 global health status scale and
showing higher OS and PFS.
Remarkably, besides low QLQ-C30 global health status
scores at treatment start, low baseline PS was signifi-
cantly associated with a greater improvement in HRQoL
throughout the treatment, presumably because of the
greater room for improvement in these patients. Thus,
although QLQ-C30 global health status scores at base-
line were lower in patients with poorer PS (18- and 21-
point differences compared to patients with better PS
for KI and ECOG, respectively), PS scores of both
groups of patients were consistent after 2 months of
chemotherapy. This finding encourages priority assess-
ment of HRQoL in patients with poorer PS. Regarding
treatment response, patients with stable disease, or par-
tial or complete response had persistently higher QLQ-
C30 global health status scores than those who pro-
gressed during the first 3 months of treatment. Of note,
HRQoL assessment was restricted to patients receiving
first-line treatment, thus gradually reducing the number
of patients in the progression subgroup. The observed
trend was consistent with data from clinical trials, indi-
cating a relationship between HRQoL and disease pro-
gression [3, 5, 6].
In addition to the general limitations of observational
designs, such as the uneven sample size across variables
due to missing data, the results of this study must be
interpreted in the context of the risk of bias associated
with a decrease in the study sample over time. This limi-
tation, also observed in previous studies assessing
HRQoL [6], implies that patients who discontinue treat-
ment because of disease progression or death—and,
therefore, are likely to have poorer HRQoL—are not
followed up any longer. Consequently, the study popula-
tion is gradually biased towards a better HRQoL as the
follow-up progresses. Nevertheless, our overall purpose
was to describe the changes in HRQoL during first-line
chemotherapy, making it necessary to interrupt follow-
up in patients initiating second-line chemotherapy. Fu-
ture studies investigating the evolution of HRQoL
throughout further treatment lines shall follow up pa-
tients during larger periods, irrespective of the treatment
outcome. Furthermore, since a specific questionnaire for
assessing HRQoL in patients with pancreatic adenocar-
cinoma has been validated [36], its use in future studies
may be more adequate.
Conclusions
In summary, our study shows that most patients starting
first-line chemotherapy improve their HRQoL throughout
the treatment, although this trend might not be applicable
Fig. 4 Evolution of the mean QLQ-C30 global health status scale scores according to the best response to first-line treatment. No evaluable
patients remained in the progression group beyond month 3 of treatment. SD: stable disease, PR: partial response, CR: complete response
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to patients who interrupt treatment early in the first few
months due to progression or toxicity. Unlike clinical tri-
als, which usually exclude patients with low PS, our study
revealed that these patients—which are likely to have
poorer HRQoL—may benefit more from chemotherapy in
terms of HRQoL. In line with the psychometric properties
reported in validation studies of the EORTC QLQ-C30, in
our experience, the administration of the questionnaire
during routine follow-up visits of patients with mPAC was
feasible. Taken together, our results suggest that, in
addition to PS, the EORTC QLQ-C30 global health status
score may help to identify mPAC patients that are more
likely to benefit from chemotherapy., and that HRQoL
may be a useful factor to stratify patients in clinical trials.
Finally, our study shows that the EORTC QLQ-C30 scale
is a responsive tool for identifying changes in HRQoL of
mPAC patients who have started first-line chemotherapy.
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